ClinicalTrials.gg
RecruitingNCT06360042Updated Apr 22, 2024

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

A Phase 2 interventional study of Adebrelimab plus Apatinib and Adebrelimab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, sponsored by Peking University Cancer Hospital & Institute. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by Peking University Cancer Hospital & Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing adebrelimab in Carcinoma, Hepatocellular — 12 open to participants now, 12 under way, 1 of them phase 3. adebrelimab · Carcinoma, Hepatocellular.

Planned enrollment
4th of 13
111 · median 52
Started
2024
with 3 others
Phase 2
8 of 13
7 open now
Primary completion
2027-03
later than 7 of 11 live
Registered
6th of 13
by date
Lead sponsor
1 of 13
Peking University Cancer Hospital & Institute

Among the 13 studies testing adebrelimab in Carcinoma, Hepatocellular, this one is the 4th largest by planned enrollment, is one of 4 that started in 2024, is one of 8 in phase 2, reaches primary completion later than 7 of the 11 other live ones, and was the 6th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

12 of the 13 studies testing adebrelimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

About adebrelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing adebrelimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.

03

Conditions studied

  • Unresectable Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced or and/or unresectable Hepatocellular Carcinoma (HCC)
  • No prior systemic therapy for HCC. Previous use of herbal therapies/traditional Chinese medicines with anti-cancer activity included in the label is allowed.
  • BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed following surgical and/or local therapy
  • At least one per v1.1
  • Performance Status of 0 or 1
  • class of A5 to B7
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously
  • Moderate-to-severe ascites with clinical symptoms
  • History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage
  • Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment
  • Known genetic or acquired hemorrhage or thrombotic tendency
  • Thrombosis or thromboembolic event within 6 months prior to the start of study treatment
  • Hypertension that can not be well controlled through antihypertensive drugs Factors to affect oral administration
  • History of hepatic encephalopathy
  • Previous or current presence of to central nervous system
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (estimated)

Study arms

  • Experimental
    1

    Adebrelimab(1200mg iv q3w) plus Apatinib(250mg po qd)

    Drug: Adebrelimab plus Apatinib

  • Experimental
    2

    Adebrelimab(1200mg iv q3w)plus Bevacizumab(15mg/kg iv q3w)

    Drug: Adebrelimab plus Bevacizumab

  • Experimental
    3

    Camrelizumab (200mg iv q2w) plus Apatinib(250mg po qd)

    Drug: Camrelizumab plus Apatinib

Interventions

06

What researchers measure

Primary outcomes

  1. 12-month overall survival rate

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. ORR

    Assessed by the investigator per RECIST v1.1 criteria

    Time frame: Up to approximately 3 years

  2. DCR

    Assessed by the investigator per RECIST v1.1 criteria

    Time frame: Up to approximately 3 years

  3. DoR

    Assessed by the investigator per RECIST v1.1 criteria

    Time frame: Up to approximately 3 years

  4. TTR

    Assessed by the investigator per RECIST v1.1 criteria

    Time frame: Up to approximately 3 years

  5. TTP

    Assessed by the investigator per RECIST v1.1 criteria

    Time frame: Up to approximately 3 years

  6. PFS

    Assessed by the investigator per RECIST v1.1 criteria

    Time frame: Up to approximately 3 years

  7. OS

    Time frame: Up to approximately 3 years

  8. safety according to NCI Common Terminology Criteria for Adverse Events, version 5.0.

    Time frame: Up to approximately 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Mar 2027, 38 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 38 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Apr 11, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06360042
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
Jan 1, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Apr 22, 2024

Study contacts

Jun Zhou
Contact
Joelbmu@126.com
13366152815
Jun Zhou
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Apatinib · Bevacizumab · Camrelizumab

Start the discussion